Author: admin

Home / admin
Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer
Post

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9, 2020 – Hayley Virgil Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation. Trilaciclib administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) helped to reduce chemotherapy-induced myelosuppression and limit the need for granulocyte colony-stimulating factors...

Should Cancer Patients Get the COVID-19 Vaccine?
Post

Should Cancer Patients Get the COVID-19 Vaccine?

Microsoft Word – Document1 Reviewed by UPMC Hillman Cancer Center January 4, 2021 In December 2020, health care workers and residents of long-term care facilities began receiving newly authorized COVID-19 vaccines. This made them some of the first in line for life-saving vaccinations developed at unprecedented speed. People with underlying health issues are next in...

COVID-19 Vaccine and Lung Cancer: Top 10 Questions Answered
Post

COVID-19 Vaccine and Lung Cancer: Top 10 Questions Answered

Posted on January 19, 2021 – 12:58pm LUNGevity Foundation This information has been reviewed and endorsed by members of LUNGevity Foundation’s Scientific Advisory Board. Who should receive the COVID-19 vaccine?  We recommend the COVID-19 vaccine for virtually all lung cancer patients, with the exception of those with a known severe reaction to polyethylene glycol or polysorbate. Medical and...

Similarities in Risk for COVID-19 and Cancer Disparities
Post

Similarities in Risk for COVID-19 and Cancer Disparities

Lisa A. Newman, Robert A. Winn and John M. Carethers DOI: 10.1158/1078-0432.CCR-20-3421 Published January 2021 Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans....

COVID-19 Resources
Post

COVID-19 Resources

The Gettysburg Cancer Center wants to continue keeping our patients informed with all the latest updates surrounding the Coronavirus Pandemic. Most people who are infected with COVID-19 will experience mild to moderate respiratory problems and recover without requiring special treatment. However, people who have an underlying medical condition like cancer, could develop more advanced health...

Treatment of malignancy associated weight loss or anorexia in patients with NSCLC
Post

Treatment of malignancy associated weight loss or anorexia in patients with NSCLC

STUDY TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC) INDICATION: Treatment of malignancy associated weight loss or anorexia in patients with NSCLC. STUDY DRUG: Anamorelin...

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer
Post

Neoadjuvant Chemohormonal Therapy With Radical Prostatectomy for Localized Prostate Cancer

By: Melissa Steele-OgusPosted: Thursday, December 10, 2020 Although radical prostatectomy remains one of the primary treatments of localized high-risk prostate cancer, biochemical progression-free survival remains lower than ideal. A study published in the Journal of Clinical Oncology compared the efficacy of radical prostatectomy versus chemohormonal therapy with androgen-deprivation therapy (ADT) plus docetaxel prior to radical prostatectomy. The...

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer
Post

Margetuximab-cmkb in Combination With Chemotherapy Approved by FDA for Metastatic Breast Cancer

By: JNCCN 360 StaffPosted: Friday, December 18, 2020 The U.S. Food and Drug Administration (FDA) recently approved the HER2-targeted monoclonal antibody margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens (one of which was for metastatic disease), according to...

First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer
Post

First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer

By: JNCCN 360 StaffPosted: Wednesday, December 2, 2020 On December 1, the U.S. Food and Drug Administration approved the radioactive diagnostic agent gallium 68 PSMA-11 (Ga 68 PSMA-11), the first drug for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate...

  • 1
  • 2
  • 8